Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

Which is better? Lactated Ringer’s solution or normal saline? The latest video in our partnership with Dr. Glaucomflecken summarizes the FLUID trial. 👉

NEJM

991,411 subscribers

87,299 views • 8 months ago •via X (Twitter)

Health & Wellness Science & Technology

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial investigating the effectiveness of shunt surgery for idiopathic normal-pressure hydrocephalus. Read the full results for free: #neurology

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial investigating the effectiveness of shunt surgery for idiopathic normal-pressure hydrocephalus. Read the full results for free: #neurology

NEJM

56,370 views • 4 months ago

The latest video in our partnership with Dr. Glaucomflecken summarizes the results of the VANISH2 trial, which compared catheter ablation versus antiarrhythmic drug therapy for ventricular tachycardia. View the full article for free:

The latest video in our partnership with Dr. Glaucomflecken summarizes the results of the VANISH2 trial, which compared catheter ablation versus antiarrhythmic drug therapy for ventricular tachycardia. View the full article for free:

NEJM

50,295 views • 1 year ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial evaluating the clinical efficacy of tecovirimat against human clade II mpox. Read the full study for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial evaluating the clinical efficacy of tecovirimat against human clade II mpox. Read the full study for free:

NEJM

37,322 views • 2 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:

NEJM

19,398 views • 6 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial assessing the efficacy and safety of intravenous tenecteplase for acute central retinal artery occlusion. Read the full study for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial assessing the efficacy and safety of intravenous tenecteplase for acute central retinal artery occlusion. Read the full study for free:

NEJM

33,682 views • 1 month ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the CORALreef Lipids trial, which assessed the efficacy of the oral PCSK9 inhibitor enlicitide in reducing LDL cholesterol levels over a 52-week period. Read the full study for free: #cardiology

Our latest video in our partnership with Dr. Glaucomflecken summarizes the CORALreef Lipids trial, which assessed the efficacy of the oral PCSK9 inhibitor enlicitide in reducing LDL cholesterol levels over a 52-week period. Read the full study for free: #cardiology

NEJM

56,231 views • 2 months ago

Internal Medicine rounds are never “aggressively boring” with Dr. G. Watch the latest video in which Dr. Glaucomflecken summarizes the PICNIC trial. Access the article for free:

Internal Medicine rounds are never “aggressively boring” with Dr. G. Watch the latest video in which Dr. Glaucomflecken summarizes the PICNIC trial. Access the article for free:

NEJM

92,472 views • 1 year ago

For patients with generalized myasthenia gravis, existing treatments reduce mortality and alleviate symptoms, but side effects and poor efficacy leave many patients seeking alternatives. The latest video in our partnership with Dr. Glaucomflecken summarizes the MINT trial. 👉

For patients with generalized myasthenia gravis, existing treatments reduce mortality and alleviate symptoms, but side effects and poor efficacy leave many patients seeking alternatives. The latest video in our partnership with Dr. Glaucomflecken summarizes the MINT trial. 👉

NEJM

137,306 views • 9 months ago

Plague is a high-consequence infectious disease with epidemic potential. The latest video in our partnership with Dr. Glaucomflecken summarizes new research evaluating ciprofloxacin versus aminoglycoside–ciprofloxacin for bubonic plague in Madagascar. 👉

Plague is a high-consequence infectious disease with epidemic potential. The latest video in our partnership with Dr. Glaucomflecken summarizes new research evaluating ciprofloxacin versus aminoglycoside–ciprofloxacin for bubonic plague in Madagascar. 👉

NEJM

44,832 views • 8 months ago

In the latest video in our partnership with Dr. Glaucomflecken, the INSEMA trial investigating axillary surgery in breast cancer is explained. Access the article for free:

In the latest video in our partnership with Dr. Glaucomflecken, the INSEMA trial investigating axillary surgery in breast cancer is explained. Access the article for free:

NEJM

130,538 views • 1 year ago

Our partnership with Dr. Glaucomflecken continues as he summarizes the final, 10-year outcomes of the CheckMate 067 trial, which investigated nivolumab plus ipilimumab in advanced melanoma. Access the article for free:

Our partnership with Dr. Glaucomflecken continues as he summarizes the final, 10-year outcomes of the CheckMate 067 trial, which investigated nivolumab plus ipilimumab in advanced melanoma. Access the article for free:

NEJM

93,144 views • 1 year ago

“Ah, it's your first gastroenteritis. It gets easier.” The latest video in our partnership with Dr. Glaucomflecken summarizes recent research on the effects of ondansetron after emergency visits in children with gastroenteritis-associated vomiting. 👉

“Ah, it's your first gastroenteritis. It gets easier.” The latest video in our partnership with Dr. Glaucomflecken summarizes recent research on the effects of ondansetron after emergency visits in children with gastroenteritis-associated vomiting. 👉

NEJM

43,226 views • 7 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the final analysis of 23 years of follow-up to evaluate the long-term effects of PSA screening. Read the full analysis for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes the final analysis of 23 years of follow-up to evaluate the long-term effects of PSA screening. Read the full analysis for free:

NEJM

185,143 views • 6 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

NEJM

46,033 views • 5 months ago

In the latest video in our partnership with Dr. Glaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free:

In the latest video in our partnership with Dr. Glaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free:

NEJM

88,397 views • 1 year ago

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation.

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation.

NEJM

98,901 views • 1 year ago

Phil, this is the kind of question with no clear answers and dozens of opinions that internists dream of! Our latest video in our partnership with Dr. Glaucomflecken summarizes the Ez-PAVE trial that evaluated the appropriate LDL cholesterol target for secondary prevention in patients with atherosclerotic cardiovascular disease. Read the full study for free: #Cardiology

Phil, this is the kind of question with no clear answers and dozens of opinions that internists dream of! Our latest video in our partnership with Dr. Glaucomflecken summarizes the Ez-PAVE trial that evaluated the appropriate LDL cholesterol target for secondary prevention in patients with atherosclerotic cardiovascular disease. Read the full study for free: #Cardiology

NEJM

47,013 views • 21 days ago

Hey, what do you think? IV or IO? This video in our partnership with Dr. Glaucomflecken summarizes new research comparing initial attempts at intraosseous or intravenous vascular access in adults who had out-of-hospital cardiac arrest. Full trial:

Hey, what do you think? IV or IO? This video in our partnership with Dr. Glaucomflecken summarizes new research comparing initial attempts at intraosseous or intravenous vascular access in adults who had out-of-hospital cardiac arrest. Full trial:

NEJM

73,321 views • 1 year ago

Could a structured exercise program after undergoing adjuvant chemotherapy for colon cancer improve survival and quality of life? The latest video in our partnership with Dr. Glaucomflecken summarizes new research. Access the article for free:

Could a structured exercise program after undergoing adjuvant chemotherapy for colon cancer improve survival and quality of life? The latest video in our partnership with Dr. Glaucomflecken summarizes new research. Access the article for free:

NEJM

71,403 views • 9 months ago

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

NEJM

144,730 views • 11 months ago